Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method of prophylaxis of a patient at risk for systemic inflammatory response syndrome and complications thereof, which comprises administering to said patient a therapeutically effective amount of a selective inhibitor of cyclooxygenase-2 having a ratio of IC₅₀ concentration (concentration inhibiting 50% of activity) for cyclooxygenase-1 to IC₅₀ concentration of cyclooxygenase-2 of greater than 1, wherein the patient at risk for systemic inflammatory response syndrome and complications thereof is a patient who has sustained at least one of trauma, burn injury, life threatening blood loss from penetrating injury, or a patient who has undergone surgery.

2-14 (canceled)

15. (original) The method of claim 1 wherein the cyclooxygenase-2 inhibitor is at least one of NS-398, celicoxib, MK-0966, or paracoxib.

16-23 (canceled)

- 24. (withdrawn) The method according to claim 1, wherein the patient at risk for systemic inflammatory response syndrome and complications thereof is a patient who has sustained trauma.
- 25. (withdrawn) The method according to claim 1, wherein the patient at risk for systemic inflammatory response syndrome and complications thereof is a patient who has sustained life threatening blood loss from penetrating injury.
- 26. (withdrawn) The method according to claim 1, wherein the patient at risk for systemic inflammatory response syndrome and complications thereof is a patient who has undergone surgery.

TOTER FK 05 27. (withdrawn) The method according to claim 1, wherein the patient at risk for systemic inflammatory response syndrome and complications thereof is a patient who has undergone burn injury.